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Vandetanib, an inhibitor of rearranged during transfection (RET) vascular endothelial growth factor, and EGFR 
tyrosine kinases, is approved in some countries for the treat-
ment of metastatic medullary thyroid cancer,1 which in many 
cases harbors RET mutations. Translocations resulting in RET 
fusion with KIF5B, CCDC6, or NCOA4 were recently dis-
covered in approximately 2% of lung adenocarcinomas, and 
are associated with younger age (<60 years), never-smoking 
status and small primary tumors (<3 cm), and N2 disease.2,3 
Preclinical studies demonstrated that cell lines with RET 
fusion had transforming capacity, and enhanced sensitivity to 
vandetanib and other RET inhibitors.3,4
In 2009, a 58-year-old white man was admitted to our 
hospital with portal vein thrombosis and an 18-mm nodule 
in the upper lobe of the left lung, which was evident on chest 
computed tomography (CT). He had a family history of throm-
boembolism, was a former smoker (5 pack-years until 1996), 
and had been exposed to polycyclic aromatic hydrocarbons as 
a road worker. Surgical staging revealed poorly differentiated 
adenocarcinoma of the lung (Fig. 1A and B) with involvement 
of ipsilateral mediastinal lymph nodes (pN2). Brain magnetic 
resonance imaging and fluorodeoxyglucose (FDG)-positron 
emission tomography (PET)/CT did not show distant metasta-
ses. After three cycles of neoadjuvant chemotherapy with cispla-
tin and docetaxel, the CT showed no change. Lobectomy with 
mediastinal lymphadenectomy revealed ypT1 ypN2 adenocar-
cinoma. The patient received postoperative radiotherapy of the 
mediastinum and regular follow-up. In April 2012, the patient 
had abdominal pain and FDG-PET/CT suggested supracla-
vicular, retroperitoneal, and inguinal lymph-node metastases. 
Lymph-node biopsy confirmed relapse of thyroid transcrip-
tion factor-1-positive lung adenocarcinoma. Sequencing was 
negative for activating mutations in EGFR, KRAS, BRAF, and 
HER2. Fluorescence in situ hybridization was negative for ALK 
or ROS1 fusion and MET amplification. After two cycles of 
chemotherapy with carboplatin and pemetrexed, abdominal pain 
increased and CT showed progressive disease. An incident myo-
cardial infarction was treated by coronary stenting, and resolved 
with normal cardiac function. In December 2012, commercial 
fluorescence in situ hybridization break-apart assays for RET 
and KIF5B were performed, and both turned out to be positive 
(Fig. 1C and D). On the basis of the preclinical rationale, the 
potential benefits and risks of vandetanib were discussed with 
the patient. After cardiac assessment, and baseline FDG-PET/
CT (Fig. 2A and D), treatment with vandetanib was started at 
a regular dosage of 300 mg once daily. After 1 week, abdomi-
nal pain resolved and FDG-PET/CT showed a decrease in FDG 
uptake and the size of the metastases (Fig. 2B and E). Vandetanib 
was tolerated well, treatment was continued, and FDG-PET/CT 
at 4 weeks confirmed the remission (Fig. 2C and F). To the best 
of our knowledge, this is the first report of a patient with lung 
adenocarcinoma and RET fusion responding to vandetanib. The 
patient provided consent for testing and treatment with a RET 
inhibitor, which is ongoing at the time of the publishing of this 
report. Of note, the tumor was refractory to previous chemo-
therapy. Cabozantinib, another RET inhibitor, is currently being 
evaluated in patients with advanced non–small-cell lung cancer 
and RET fusion in a phase II trial (NCT01639508).
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FIGURE 1. A, Hematoxylin and 
eosin staining, showing highly 
pleomorphic adenocarcinoma with 
multinucleated cells and intranu-
clear inclusions. B, TTF-1 immuno-
histochemistry with strong nuclear 
staining. C, FISH with KIF5B dual 
color break-apart probe, showing 
increase of total signals, consistent 
with polysomy, and split red and 
green signals (arrows), consistent 
with KIF5B rearrangement. D, FISH 
with RET dual-color break-apart 
probe, showing clearly separated 
red and green signals (arrows), con-
sistent with RET rearrangement. The 
hybridization pattern was consistent 
with gene rearrangement in 87% 
of tumor cell nuclei, exceeding the 
cutoff values of 17% and 15% for 
KIF5B and RET, respectively.5 KIF5B 
and RET probes were purchased 
from ZytoVision, Bremerhaven, 
Germany. FISH, fluorescence in situ 
hybridization; TTF, thyroid  
transcription factor.
FIGURE 2. A, and (D), Baseline 
FDG-PET/CT with increased uptake 
in a right-sided supraclavicular 
lymph-node metastasis (short arrow), 
retroperitoneal lymph-node metastasis 
(SUV max 7.8), and inguinal nodes. 
Uptake in the left larynx (arrowhead) 
caused by VOX implant for vocal cord 
paralysis. B, and (E), FDG-PET/CT on 
day 8 after start of treatment with 
vandetanib, showing disappearance 
of FDG uptake in the supraclavicular 
metastasis (size change from 8 × 8 to 
5 × 5 mm), and significant reduction 
of FDG uptake in the retroperitoneal 
metastasis (long arrow, SUV max 
4.1, size change from 22 × 12 to 
20 × 12 mm). C, and (F), FDG-PET/
CT on day 28, after start of treatment 
with vandetanib, with confirmed 
response of supraclavicular and ret-
roperitoneal metastases (long arrow, 
SUV max 2.7), and disappearance of 
FDG uptake in the inguinal nodes (size 
change from 16 × 8 to 10 × 5 mm on 
the right, and from 10 × 6 to 8 × 5 mm 
on the left). FDG, fludeoxyglucose; 
PET, positron emission tomography; 
CT, computed tomography; SUV max, 
maximum standardized uptake value.
